Founders & CXOs
Oval Fertility and Merck India Have Signed an MoU to Strengthen Reproductive Care Standards — India's Fertility Sector Consolidates Around Quality
By Mustafa Shariff, Editro in Chief · June 17, 2026 · 2 min read
Summary
- Oval Fertility + Merck India MoU: Strengthening Reproductive Care Standards Across India's Growing IVF Market
- Oval Fertility has signed an MoU with Merck India to advance reproductive care standards. Here is the full context of India's fertility sector consolidation and quality upgrade cycle.
"Oval Fertility is committed to making world-class reproductive care accessible to every couple in India. This collaboration with Merck brings together scientific expertise and clinical innovation to help us advance treatment protocols and improve outcomes for our patients."
Oval Fertility has signed a Memorandum of Understanding with Merck India — the Indian subsidiary of Merck KGaA, the German pharmaceutical and life sciences company — to strengthen reproductive care standards across Oval's fertility centre network. The partnership establishes a collaborative framework for scientific education, clinical protocol development, training programmes for fertility specialists, and quality improvement initiatives aligned with globally recognised standards in assisted reproduction.
Merck KGaA is the world's leading fertility drugs company — its pharmaceutical division produces the gonadotropin medications (follicle-stimulating hormone, luteinising hormone, and their recombinant analogues) that form the pharmacological backbone of IVF treatment protocols globally. Merck's fertility portfolio includes brands that are standard of care in reproductive medicine clinics across Europe, North America, and increasingly India — Gonal-f (recombinant FSH), Luveris (recombinant LH), Cetrotide (cetrorelix, a GnRH antagonist), and Pergoveris (combined FSH/LH). The company's presence as a partner and scientific collaborator to fertility clinics gives it unique insight into clinical practice standards, outcomes data, and the protocol optimisations that differentiate high-performing IVF centres from average-performing ones.
India's Fertility Market in Transformation
India's assisted reproduction sector is experiencing two simultaneous trends that make the Oval-Merck MoU significant: rapid capacity expansion and an accelerating quality gap between leading centres and the broad field of IVF clinics.
India now has more IVF clinics than any other country except the United States — estimated at over 2,000 active centres — serving a patient population driven by high rates of infertility (affecting an estimated 10-15% of Indian couples), delayed childbearing in urban professional populations, and growing insurance coverage for fertility treatment. The clinical volumes are large: India performs approximately 250,000-300,000 IVF cycles annually, with growth rates of 15-20% per year.
The quality gap is where the consolidation story becomes commercially and clinically important. Success rates across Indian IVF clinics vary enormously — from leading centres achieving live birth rates of 50-60% per embryo transfer cycle to lower-tier clinics achieving 25-30% or less. This variation reflects differences in laboratory quality, embryologist skill, stimulation protocol selection, genetic testing capabilities, and patient management practices — all of which the Oval-Merck collaboration is designed to improve at the network level.
The Week's Fertility Sector Context
The Oval-Merck MoU arrives in the same week as India's largest maternity and fertility consolidation story: the Apollo Cradle-Apollo Fertility-Cloudnine ₹1,550 crore merger (covered in BHC Media's June 5 edition). The convergence of consolidation-at-scale (Apollo-Cloudnine) and quality partnership development (Oval-Merck) reflects the same underlying market dynamic from two different strategic approaches: the fertility sector recognises that competitive advantage in India's growing ART market will be built on clinical outcomes and treatment quality, not just geographic network scale.
BHC Perspective
At Bengaluru Health Community, the Oval Fertility-Merck MoU is a quality infrastructure story for India's fertility sector. For BHC founders building in reproductive health technology, embryology support platforms, or patient management tools for IVF clinics — the quality standardisation agenda that Merck and Oval are building around creates a commercial environment where technology solutions that improve protocol adherence and clinical outcomes have a clear value proposition.
Frequently Asked Questions
Q: What is the Oval Fertility-Merck India MoU?
A: A partnership between Oval Fertility and Merck India to strengthen reproductive care standards across Oval's IVF network, covering scientific education, clinical protocol development, specialist training, and quality improvement initiatives aligned with global assisted reproduction standards.
Q: Why is Merck the right partner for IVF quality development?
A: Merck KGaA is the world's leading fertility drugs company, supplying gonadotropins and ART medications globally. Its scientific expertise in IVF pharmacology and its insight into clinical best practices across global fertility markets make it uniquely positioned to support protocol development and quality improvement.
Q: What is India's IVF market context?
A: India has over 2,000 IVF clinics and performs 250,000-300,000 cycles annually, with 15-20% annual growth. Success rates vary enormously between leading centres (50-60% live birth rates) and the broad field, creating a quality gap that partnerships like Oval-Merck are designed to close.